The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

C3G and IC-MPGN are rare, incurable diseases that have similar symptoms and progression. While they are distinct conditions, they both cause kidney damage and have a high risk of kidney failure.

Visual navigation systems are susceptible to complex environments, while inertial navigation systems (INS) are not affected by external factors. Hence, we present IC-GVINS, a robust, real-time, ...